AAAAAA

   
Results: 1-14 |
Results: 14
Chemotherapy for advanced colorectal cancer - Reply
Authors: Michael, M Zalcberg, J
Citation: M. Michael et J. Zalcberg, Chemotherapy for advanced colorectal cancer - Reply, BR MED J, 322(7280), 2001, pp. 233-233
Randomized trial of coordinated psychosocial interventions based on patient self-assessments versus standard care to improve the psychosocial functioning of patients with cancer
Authors: McLachlan, SA Allenby, A Matthews, J Wirth, A Kissane, D Bishop, M Beresford, J Zalcberg, J
Citation: Sa. Mclachlan et al., Randomized trial of coordinated psychosocial interventions based on patient self-assessments versus standard care to improve the psychosocial functioning of patients with cancer, J CL ONCOL, 19(21), 2001, pp. 4117-4125
Regulation of MDR1 gene expression: emerging concepts
Authors: Kantharidis, P El-Osta, S de Silva, M Lee, G Hu, XF Zalcberg, J
Citation: P. Kantharidis et al., Regulation of MDR1 gene expression: emerging concepts, DRUG RESIST, 3(2), 2000, pp. 99-108
MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines
Authors: Zalcberg, J Hu, XF Slater, A Parisot, J El-Osta, S Kantharidis, P Chou, ST Parkin, JD
Citation: J. Zalcberg et al., MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines, PROSTATE C, 3(2), 2000, pp. 66-75
A phase I trial of docetaxel and gemcitabine in patients with advanced cancer
Authors: Rischin, D Boyer, M Smith, J Millward, M Michael, M Bishop, J Zalcberg, J Davison, J Emmett, E McClure, B
Citation: D. Rischin et al., A phase I trial of docetaxel and gemcitabine in patients with advanced cancer, ANN ONCOL, 11(4), 2000, pp. 421-426
Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck
Authors: Clarke, SJ Zalcberg, J Olver, I Mitchell, PLR Rischin, D Dalley, D Green, M Davidson, YE
Citation: Sj. Clarke et al., Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck, ANN ONCOL, 11(2), 2000, pp. 239-241
Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer
Authors: Basser, RL Underhill, C Davis, I Green, MD Cebon, J Zalcberg, J MacMillan, J Cohen, B Marty, J Fox, RM Begley, CG
Citation: Rl. Basser et al., Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer, J CL ONCOL, 18(15), 2000, pp. 2852-2861
Use of (F-18)-fluorodeoxyglucose positron emission tomography in monitoring response of recurrent neurotropic desmoplastic melanoma to radiotherapy
Authors: Hannah, A Feigen, M Quong, G Akhurst, T Berlangieri, SU Zimet, A Zalcberg, J McKay, WJ Scott, AM
Citation: A. Hannah et al., Use of (F-18)-fluorodeoxyglucose positron emission tomography in monitoring response of recurrent neurotropic desmoplastic melanoma to radiotherapy, OTO H N SUR, 122(2), 2000, pp. 304-306
Does biomodulation of 5-fluorouracil improve results? Arbiter
Authors: Rischin, D Zalcberg, J
Citation: D. Rischin et J. Zalcberg, Does biomodulation of 5-fluorouracil improve results? Arbiter, EUR J CANC, 35(2), 1999, pp. 192-194
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors
Authors: Talbot, SM Westerman, DA Grigg, AP Toner, GC Wolf, M Bishop, J McKendrick, J Zalcberg, J Levi, J Fox, RM Green, MD
Citation: Sm. Talbot et al., Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors, ANN ONCOL, 10(8), 1999, pp. 907-914
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel withperipheral blood progenitor cell and filgrastim support for metastatic andlocally advanced breast cancer: Results of a phase I study
Authors: Prince, HM Millward, MJ Rischin, D Blakey, D Francis, P Gates, P Chapple, P Quinn, M Juneja, S Wolf, M Januszewicz, EH Seymour, JF Brettell, M Strickland, A Zalcberg, J Richardson, G Scarlett, J Briggs, P Toner, GC
Citation: Hm. Prince et al., Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel withperipheral blood progenitor cell and filgrastim support for metastatic andlocally advanced breast cancer: Results of a phase I study, ANN ONCOL, 10(4), 1999, pp. 479-481
Absolute quantitation of MDR1 transcripts using heterologous DNA standards- Validation of the competitive RT-PCR (CRT-PCR) approach
Authors: El-Osta, A Kantharidis, P Zalcberg, J
Citation: A. El-osta et al., Absolute quantitation of MDR1 transcripts using heterologous DNA standards- Validation of the competitive RT-PCR (CRT-PCR) approach, BIOTECHNIQU, 26(6), 1999, pp. 1114
Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line
Authors: Hu, XF Slater, A Rischin, D Kantharidis, P Parkin, JD Zalcberg, J
Citation: Xf. Hu et al., Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line, BR J CANC, 79(5-6), 1999, pp. 831-837
Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number
Authors: Zalcberg, J Kerr, D Seymour, L Palmer, M
Citation: J. Zalcberg et al., Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number, EUR J CANC, 34(12), 1998, pp. 1871-1875
Risultati: 1-14 |